Drugs / MR-107A-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04571515 | Sep → Dec 2020 | — | Mylan Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR-107A-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04571515 ↗ |
| Route | Oral | “Oral tablet” NCT04571515 ↗ |